BioVie Inc/$BIVI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About BioVie Inc
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.
Ticker
$BIVI
Sector
Primary listing
Employees
13
Headquarters
Website
BioVie Inc Metrics
BasicAdvanced
$13m
-
-$3.49
0.65
-
Price and volume
Market cap
$13m
Beta
0.65
52-week high
$9.56
52-week low
$1.06
Average daily volume
108k
Financial strength
Current ratio
9.966
Quick ratio
9.017
Long term debt to equity
1.367
Total debt to equity
1.895
Interest coverage (TTM)
-1,088.49%
Profitability
EBITDA (TTM)
-20.366
Management effectiveness
Return on assets (TTM)
-61.04%
Return on equity (TTM)
-106.43%
Valuation
Price to book
0.86
Price to tangible book (TTM)
0.88
Price to free cash flow (TTM)
-0.5
Free cash flow yield (TTM)
-200.00%
Free cash flow per share (TTM)
-3.58
Growth
Earnings per share change (TTM)
-79.01%
3-year earnings per share growth (CAGR)
-72.44%
BioVie Inc News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs